Effect of long biliopancreatic limb length in laparoscopic Roux-en-Y Gastric Bypass on weight loss and comorbidities in patients with morbid obesity: a prospective randomized control trial

Effect of long biliopancreatic limb length in laparoscopic Roux-en-Y Gastric Bypass on weight loss and comorbidities in patients with morbid obesity: a prospective randomized control trial - The Elegance trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44795

Enrollment

280

Registered

2012-06-13

Start date

2012-06-29

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(morbide) obesitas morbid obesity overweight

Interventions

Standard RYGB with biliopancreatic limb of 50 cm and Roux limb of 175 cm versus Long biliopancreatic limb RYGB with biliopancreatic limb of 150 cm and Roux limb of 50 cm.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patient eligible for bariatric surgery according Fried guidelines;Primary Gastric bypass - BMI 35 - 40 with a comorbidity - or BMI > 40;Redo- operation - medical history: gastric sleeve/ mason / gastric band - all BMI levels

Exclusion criteria

Exclusion criteria: - Exclusion criteria for bariatric surgery (Fried Guidelines) - Patients with language problems that intervens to follow medical advises - Genetic diseases that intervens to follow medical advises - Chronic bowel diseases - Nefrologic (MDRD

Design outcomes

Primary

Measure	Time frame
Weight reduction; excess weight loss (%EWL).	—

Secondary

Measure	Time frame
a. Decrease in comorbidities: diabetes mellitus, hypertension, hypercholesterolemia, artrosis b. Quality of life: SF-36 and BAROS c. Complicaties and re-operations: bleeding, woundinfections, intra-abdominal abces, anastomosis leakage, vitamine definciencies	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)